CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C42.339699%2C-71.105003%7C34.129601%2C-117.971001%7C40.756279%2C-73.691421%7C33.506452%2C-86.802573%7C40.839802%2C-73.939301%7C40.764198%2C-73.956703%7C44.022499%2C-92.466698%7C33.659052%2C-111.95645%7C30.2628%2C-81.441299%7C29.707199%2C-95.396698%7C40.8839%2C-74.055603%7C42.337502%2C-71.108101%7C42.898499%2C-78.864998%7C33.909199%2C-84.353996%7C41.255507%2C-95.979724%7C36.152048%2C-86.801153)
Participating Centers
There are 16 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- BMS-986393 (CC-95266)
- Iberdomide
- Mezigdomide
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.